Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163
What this trial is testing
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Who this might be right for
Bladder Cancer
Memorial Sloan Kettering Cancer Center 45